| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Roberto Pili | |
| Li Shen | |||
| Neha Gupta | |||
| Omar Al-Ustwani | |||
| P2860 | cites work | Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides | Q21145828 |
| Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis | Q84595151 | ||
| Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors | Q21245714 | ||
| Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells | Q24308708 | ||
| Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche | Q24606366 | ||
| Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 | ||
| Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 | ||
| Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein | Q24641894 | ||
| Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer | Q24647897 | ||
| Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells | Q24658240 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| CYP1A1: friend or foe? | Q28259718 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme | Q33404163 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials | Q33898885 | ||
| Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor | Q33947807 | ||
| The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer | Q34013840 | ||
| Current Management of Castrate-Resistant Prostate Cancer | Q34111641 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer | Q34217642 | ||
| Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). | Q34250496 | ||
| Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice | Q34405669 | ||
| Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer | Q34563829 | ||
| The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts | Q34610434 | ||
| ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2 | Q35130971 | ||
| Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma | Q35833169 | ||
| Regulation of tumor angiogenesis by thrombospondin-1. | Q36365861 | ||
| HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion | Q37098976 | ||
| Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. | Q37758250 | ||
| Growth/differentiation factor-15: prostate cancer suppressor or promoter? | Q37988746 | ||
| Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings. | Q38020235 | ||
| Advanced clinical states in prostate cancer | Q38053681 | ||
| Radium-223 for the treatment of prostate cancer | Q38073823 | ||
| Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer | Q38093471 | ||
| Growth differentiation factor-15 (GDF-15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). | Q39218029 | ||
| Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma | Q39517040 | ||
| Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts | Q41836745 | ||
| Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves | Q41952605 | ||
| The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis | Q44133715 | ||
| Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines | Q46238133 | ||
| Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. | Q53452479 | ||
| Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone | Q60504419 | ||
| A treatment for metastasis of murine ocular melanoma | Q67930666 | ||
| Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma | Q68796580 | ||
| Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers | Q71693655 | ||
| Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer | Q73589315 | ||
| Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate | Q77359737 | ||
| The treatment of hormone-refractory prostate cancer: docetaxel and beyond | Q79190111 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 223-34 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer | |
| P478 | volume | 7 |
| Q39333529 | Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. |
| Q38267175 | Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents |
| Q88777747 | Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9 |
| Q37113485 | Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer |
Search more.